Published in
Future Medicine, Future Oncology, 21(11), p. 2881-2891, 2015
DOI: 10.2217/fon.15.158
Links
Tools
Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients
,
Orazio Caffo,
Lucia Fratino ,
Giovanni Lo Re,
Umberto Basso,
Alessandro D'Angelo,
Alessandro D’Angelo,
Maddalena Donini,
Francesco Verderame,
Raffaele Ratta,
Giuseppe Procopio ,
Enrico Campadelli,
Francesco Massari,
Donatello Gasparro,
Paola Ermacora
and other authors.
Full text: Download
Abstract
Background: The objective of this study was to analyze the impact of visceral metastases in castration-resistant prostate cancer (CRPC) treated with abiraterone. Materials & methods: All CRPC patients received abiraterone 1000 mg daily plus prednisone 10 mg orally daily. Liver and lung metastases were considered as visceral metastases. Results: Of 265 CRPC patients, 49 had visceral metastases. Results on progression-free survival were not significantly different in patients with or without visceral metastases. Conversely, the median overall survival between the two groups was 12.4 and 18.5 months (p = 0.01), respectively, and median overall survival of patients with liver-only disease versus other sites was 10.5 versus 18.5 months (p = 0.006), respectively. Conclusion: Visceral disease appears to be an important predictor of clinical outcome in CRPC patients treated with abiraterone.